Company intelligence / Profile preview
Immunic Therapeutics
New York City, New York, United Statesimux.com ↗
- Ownership
- Public · IMUX
- Development stage
- Other
01
Overview
Vidofludimus calcium (IMU-838) has shown therapeutic activity in phase 2 clinical trials for relapsing-remitting MS, progressive MS, and moderate-to-severe ulcerative colitis. IMU-856 demonstrated positive effects in celiac disease patients during a phase 1/1b trial, showing protection of gut architecture, symptom improvement, biomarker response, and enhanced nutrient absorption.
- Therapeutic areas
- GastroenterologyDermatologyOncologyNeurology
- Modalities
- Small molecules, orally administered
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Financials
- Market cap
- $99.9M
- Total revenue
- $0
- Enterprise value
- $-54.7M
Beyond the preview
Go deeper on Immunic Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunic Therapeutics.